Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 458431, 6 pages
http://dx.doi.org/10.1155/2010/458431
Review Article

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer

Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita 879-5593, Japan

Received 24 March 2009; Revised 6 September 2009; Accepted 13 October 2009

Academic Editor: Charles F. Levenback

Copyright © 2010 Noriyuki Takai and Hisashi Narahara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [22 citations]

The following is the list of published articles that have cited the current article.

  • Gareth J Sanger, Lin Chang, Chas Bountra, and Lesley A Houghton, “Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.,” Therapeutic advances in gastroenterology, vol. 3, no. 5, pp. 291–305, 2010. View at Publisher · View at Google Scholar
  • Curtis Balch, and Kenneth P. Nephew, “The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer,” Cancer Biomarkers, vol. 8, no. 4-5, pp. 203–221, 2010. View at Publisher · View at Google Scholar
  • Sibaji Sarkar, and Douglas V. Faller, “T-Oligos Inhibit Growth and Induce Apoptosis in Human Ovarian Cancer Cells,” Oligonucleotides, vol. 21, no. 1, pp. 47–53, 2011. View at Publisher · View at Google Scholar
  • Alessandro Bovicelli, Giuseppina D'Andrilli, and Antonio Giordano, “New Players in Ovarian Cancer,” Journal of Cellular Physiology, vol. 226, no. 10, pp. 2500–2504, 2011. View at Publisher · View at Google Scholar
  • Huaping Chen, Tabitha M Hardy, and Trygve O Tollefsbol, “Epigenomics of ovarian cancer and its chemoprevention.,” Frontiers in genetics, vol. 2, pp. 67, 2011. View at Publisher · View at Google Scholar
  • Curt Balch, Kaleb Naegeli, Seungyoon Nam, Brett Ballard, Alan Hyslop, Christina Melki, Elizabeth Reilly, Man-Wook Hur, and Kenneth P. Nephew, “A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells,” Cancer Biology & Therapy, vol. 13, no. 8, pp. 681–693, 2012. View at Publisher · View at Google Scholar
  • Pei-Shi Ong, Xin-Qiao Wang, Ha-Shu Lin, Sui-Yung Chan, and Paul C. Ho, “Synergistic effects of suberoylanilide hydroxamic acid combined with cispiatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells,” International Journal Of Oncology, vol. 40, no. 5, pp. 1705–1713, 2012. View at Publisher · View at Google Scholar
  • E. Prosperi, O. Cazzalini, and L. A. Stivala, “The Cyclin-Dependent Kinase Inhibitor p21(CDKN1A) as a Target of Anti-Cancer Drugs,” Current Cancer Drug Targets, vol. 12, no. 2, pp. 85–96, 2012. View at Publisher · View at Google Scholar
  • Susan K Murphy, “Targeting the epigenome in ovarian cancer,” Future Oncology, vol. 8, no. 2, pp. 151–164, 2012. View at Publisher · View at Google Scholar
  • J. Chang, D. S. Varghese, M. C. Gillam, M. Peyton, B. Modi, R. L. Schiltz, L. Girard, and E. D. Martinez, “Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide,” British Journal Of Cancer, vol. 106, no. 1, pp. 116–125, 2012. View at Publisher · View at Google Scholar
  • Leonhard M. Henkes, Patricia Haus, Felix Jäger, Joachim Ludwig, and Franz-Josef Meyer-Almes, “Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases,” Bioorganic & Medicinal Chemistry, vol. 20, no. 2, pp. 985–995, 2012. View at Publisher · View at Google Scholar
  • Mourad W. Ali, Ercan Cacan, Yuying Liu, Jennifer Young Pierce, William T. Creasman, Mandi M. Murph, Rajgopal Govindarajan, Scott T. Eblen, Susanna F. Greer, and Shelley B. Hooks, “Transcriptional Suppression, DNA Methylation, and Histone Deacetylation of the Regulator of G-Protein Signaling 10 (RGS10) Gene in Ovarian Cancer Cells,” PLoS ONE, vol. 8, no. 3, pp. e60185, 2013. View at Publisher · View at Google Scholar
  • Hongtu Chao, Li Wang, Jingli Hao, Jie Ni, Lei Chang, Peter H. Graham, John H. Kearsley, and Yong Li, “Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro,” Cancer Letters, vol. 329, no. 1, pp. 17–26, 2013. View at Publisher · View at Google Scholar
  • Qi Wang, Xia Liu, Danrong Li, Li Li, Fuqiang Yin, and Wei Zhang, “Tumor suppressor genes associated with drug resistance in ovarian cancer (Review),” Oncology Reports, vol. 30, no. 1, pp. 3–10, 2013. View at Publisher · View at Google Scholar
  • Deborah J. Marsh, Jaynish S. Shah, and Alexander J. Cole, “Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets,” Frontiers in Oncology, vol. 4, 2014. View at Publisher · View at Google Scholar
  • Xia Liu, Yutao Gao, Yi Lu, Jian Zhang, and Li Li, “Upregulation of NEK2 is associated with drug resistance in ovarian cancer,” Oncology Reports, vol. 31, no. 2, pp. 745–754, 2014. View at Publisher · View at Google Scholar
  • Magdalena Kusaczuk, Rafał Krętowski, Marek Bartoszewicz, and Marzanna Cechowska-Pasko, “Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line,” Tumor Biology, 2015. View at Publisher · View at Google Scholar
  • Claire Verschraegen, Karen Lounsbury, Alan Howe, and Marc Greenblatt, “Therapeutic implications for ovarian cancer emerging from the Tumor Cancer Genome Atlas,” Translational Cancer Research, vol. 4, no. 1, pp. 40–59, 2015. View at Publisher · View at Google Scholar
  • Fernanda Silva, Ana Félix, and Jacinta Serpa, “Functional redundancy of the Notch pathway in ovarian cancer cell lines,” Oncology Letters, vol. 12, no. 4, pp. 2686–2691, 2016. View at Publisher · View at Google Scholar
  • Øystein Helland, Mihaela Popa, Katharina Bischof, Bjørn Tore Gjertsen, Emmet McCormack, and Line Bjørge, “The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer,” Plos One, vol. 11, no. 6, pp. e0158208, 2016. View at Publisher · View at Google Scholar
  • Himavanth R Gatla, Yue Zou, Mohammad M Uddin, and Ivana Vancurova, “Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.,” Oncotarget, vol. 8, no. 41, pp. 70798–70810, 2017. View at Publisher · View at Google Scholar
  • Himavanth R. Gatla, Yue Zou, Mohammad M. Uddin, Bipradeb Singha, Pengli Bu, Ales Vancura, and Ivana Vancurova, “Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells,” Journal of Biological Chemistry, vol. 292, no. 12, pp. 5043–5054, 2017. View at Publisher · View at Google Scholar